

To: Valued Customer
From: Biocept Customer Service Team
Re: Enhancement to our CTC Capture and FISH Process

IMPORTANT

Biocept CTC Update

Biocept is delighted to announce a significant enhancement to our Target Selector™ CTC platform.

Our new technology enhancement dramatically improves Biocept's ability to identify CTCs captured within the blood samples of your patient's diagnosed with cancer. In addition, new proprietary applications in our FISH testing process will allow Biocept to provide substantial improvement in providing more results based on tests ordered.

Naturally, these new processes are validated in accordance with all federal, state and College of Pathology (CAP) regulations and guidelines and are within the scope of our CLIA license.

Please note that these new technologies may provide results that differ from prior tests for the patients you have been monitoring with CTCs and for FISH testing ordered. It is Biocept's recommendation that you consider ordering another CTC test for your patients in the near future to obtain "re-baselined" results.

We look forward to providing you and your patient's continual enhancements for CTC testing. Please contact us if you have any questions.

Kind regards,
Customer Service